Article
Oncology
Katherine B. Peters, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, Maria W. Freeman, Dina M. Randazzo, Annick Desjardins, Henry S. Friedman
Summary: A placebo-controlled, double-blind study showed that low-dose naltrexone (LDN) did not have a significant impact on quality of life and fatigue in patients with high-grade glioma (HGG) during concurrent chemotherapy and radiation therapy.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Immunology
Patricia J. McLaughlin, Laura B. Odom, Peter A. Arnett, Shannon Orehek, Gary A. Thomas, Ian S. Zagon
Summary: This study investigated the effects of low-dose naltrexone (LDN) therapy on anxiety and depression levels in persons with multiple sclerosis (PwMS) during the early months of COVID-19. The results showed that PwMS who were prescribed LDN, either alone or as an adjuvant therapy, had significantly lower self-reported anxiety and depression scores compared to those on oral disease-modifying therapies.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Bertram Pitt, Ashley M. Tate, David Gluck, Robert S. Rosenson, Sascha N. Goonewardena
Summary: COVID-19 is characterized by dysregulation of the immune system and thrombosis. Traditional anticoagulation strategies may increase bleeding risk, so finding new strategies that can regulate the immune system and solve thrombosis issues would be beneficial. This commentary discusses the unique properties of low dose naltrexone (LDN) and suggests it could be a novel therapeutic strategy for COVID-19.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Review
Immunology
Na Qu, Yiming Meng, Mike K. Handley, Chunyan Wang, Fengping Shan
Summary: Naltrexone is a nonspecific opioid antagonist used in various disorders, while low-dose naltrexone demonstrates significant inhibition in cancer treatment and immune remodeling against tumor invasion and chemical toxicity, making it a focus of anticancer research.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
C. Noelle Driver, Ryan S. D'Souza
Summary: Current pharmacologic treatments for fibromyalgia and chronic pain disorders have limited analgesic effects, prompting the exploration of low-dose naltrexone (LDN) as a potential option. This study investigated the real-world prescribing practices of LDN, assessed the perceived benefit of LDN in managing pain symptoms, and identified predictors for benefit or discontinuation. Out of 115 patients included in the analysis, 65% reported a benefit in their pain symptoms while taking LDN, and 36% discontinued LDN by the most recent follow-up. LDN showed potential as a safe pharmacologic option for chronic pain conditions and should be further investigated in controlled clinical trials.
Article
Medicine, General & Internal
Laure M. Fijen, Marc A. Riedl, Laura Bordone, Jonathan A. Bernstein, Jason Raasch, Raffi Tachdjian, Timothy Craig, William R. Lumry, Michael E. Manning, Veronica J. Alexander, Kenneth B. Newman, Alexey Revenko, Brenda F. Baker, Charvi Nanavati, A. Robert MacLeod, Eugene Schneider, Danny M. Cohn
Summary: In this small phase 2 trial, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo among patients with hereditary angioedema. The change in quality of life score was more significant in the donidalorsen group, with a relatively lower incidence of adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Clinical Neurology
Juan Yang, Kyung-Min Shin, Alex Do, Dennis M. Bierle, Abd Moain Abu Dabrh, Ziying Yin, Brent A. Bauer, Arya B. Mohabbat
Summary: 《Safety and efficacy of low-dose naltrexone for fibromyalgia treatment》This study aimed to systematically assess the current evidence on the safety and efficacy of low-dose naltrexone (LDN) for the treatment of fibromyalgia (FM). A comprehensive search produced 805 articles, and 9 articles were selected for evaluation. LDN was found to be effective in the symptomatic management of FM, with no severe adverse events reported. However, the level of scientific evidence is limited, and future well-designed trials with large sample sizes are required.
JOURNAL OF PAIN RESEARCH
(2023)
Article
Medicine, General & Internal
Justinas Jonusas, Ausvydas Patasius, Mantas Trakymas, Jonas Venius, Ernestas Janulionis, Giedre Smailyte, Marius Kincius
Summary: This study aims to compare the quality of life and efficacy of patients diagnosed with prostate cancer before and after treatment with different methods, including focal high-dose-rate brachytherapy, focal low-dose-rate brachytherapy, and active surveillance. The results of the study will be published in peer-reviewed journals and presented at conferences.
Review
Biochemistry & Molecular Biology
Praneet Dara, Zeba Farooqui, Fackson Mwale, Chungyoul Choe, Andre J. van Wijnen, Hee-Jeong Im
Summary: Chronic pain conditions caused by arthritis have devastating effects on both individuals and society. The main objective of pharmacological treatments is to reduce pain, and several types of drugs have been considered. Naltrexone, an oral-activated opioid antagonist, has been shown to have beneficial effects on chronic pain conditions such as fibromyalgia and multiple sclerosis.
Article
Nutrition & Dietetics
Raffaele Serra, Nicola Ielapi, Andrea Bitonti, Stefano Candido, Salvatore Fregola, Alessandro Gallo, Antonio Loria, Lucia Muraca, Luca Raimondo, Luminita Velcean, Simone Guadagna, Luca Gallelli
Summary: This study investigated the effectiveness of a new formulation of diosmin in relieving symptoms and improving quality of life in patients with CVD. The results showed that the low-dose mu smin(R) Plus was safe and effective in reducing leg edema, pain, and clinical severity scores, leading to an overall improvement in quality of life for the subjects.
Article
Immunology
Hector Bonilla, Lu Tian, Vincent C. Marconi, Robert Shafer, Grace A. Mccomsey, Mitchel Miglis, Philip Yang, Andres Bonilla, Lauren Eggert, Linda N. Geng
Summary: The global prevalence of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) is approximately 43%, while in the United States, around 11% of individuals who have been infected with SARSCoV-2 experience long COVID. The underlying causes of PASC are still under investigation, and there are currently no FDA-approved therapies. Naltrexone, a medication with anti-inflammatory and immunomodulatory properties, has shown potential as a therapeutic intervention for PASC, but further rigorous clinical trials are needed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Mira Patel, William Tyler Turchan, Christopher G. G. Morris, Dana Augustine, Tianming Wu, Aytek Oto, Gregory P. P. Zagaja, Stanley L. L. Liauw
Summary: This study evaluates the outcomes of low dose rate brachytherapy for prostate cancer and explores factors associated with toxicity and quality of life. The results show that monotherapy with brachytherapy is effective for unfavorable-intermediate risk disease and has low rates of late side effects. However, there were mild changes in urinary and sexual health over time. The study suggests that MRI can be used to safely select patients for brachytherapy treatment.
Article
Multidisciplinary Sciences
Edyta Sutkowska, Paulina Fortuna, Jerzy Wisniewski, Karolina Sutkowska, Pawel Hodurek, Andrzej Gamian, Bernadetta Kaluza
Summary: This study found that patients with pre-diabetes can reach therapeutic concentration with low dose of metformin, and body weight may impact the drug concentration in serum.
SCIENTIFIC REPORTS
(2021)
Article
Respiratory System
Sahajal Dhooria, Inderpaul Singh Sehgal, Ritesh Agarwal, Valliappan Muthu, Kuruswamy Thurai Prasad, Pooja Dogra, Uma Debi, Mandeep Garg, Amanjit Bal, Nalini Gupta, Ashutosh Nath Aggarwal
Summary: This study found that high-dose prednisolone was not superior to a lower dose in improving outcomes or health-related quality of life in sarcoidosis and was associated with similar adverse effects.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Oncology
Mattias Hammarstroem, Marike Gabrielson, Alessio Crippa, Andrea Discacciati, Martin Eklund, Cecilia Lundholm, Magnus Baecklund, Yvonne Wengstroem, Signe Borgquist, Jenny Bergqvist, Mikael Eriksson, Jose Tapia, Kamila Czene, Per Hall
Summary: Based on questionnaire data from a randomized controlled trial, low-dose tamoxifen was associated with fewer side effects compared to standard dose tamoxifen in healthy women. These side effects mainly included hot flashes, night sweats, cold sweats, vaginal discharge, and muscle cramps. The dose-dependent difference was primarily influenced by menopausal status.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medicine, Research & Experimental
Tong Cheng, Zhusheng Chen, Yibin Qin, Xiang Zhu, Hongsheng Chen, Zhongling Xu, Xiaqing Ma
Summary: Morphine is commonly used and effective for pain relief, but its side effect of itching limits its clinical use. This paper discusses the potential of using esketamine to treat morphine-induced itching.
MEDICAL HYPOTHESES
(2024)
Article
Medicine, Research & Experimental
Sung Eun Lee, Eunjung Park, Ji-yun Kim, HyukHoon Kim
Summary: Hyperbaric oxygen therapy (HBOT) is a potential therapeutic modality that has been recognized for its favorable mechanisms in various diseases, including sepsis-associated encephalopathy (SAE). HBOT has neuroprotective effects through its anti-inflammatory and antiapoptotic effects as well as increased tissue oxygenation capacity. However, there are caveats and limitations in applying HBOT in sepsis.
MEDICAL HYPOTHESES
(2024)
